FrancophonIA/ELRC3.0 huggingface dataset:
English: The majority of a dose of raloxifene and glucuronide metabolites are excreted within 5 days and are found primarily in the faeces, with less than 6 % excreted in urine.
Slovenian: Izločanje Večji del odmerka raloksifena in njegovih glukuronidnih presnovkov se izloči v roku 5 dni in jih najdemo predvsem v blatu, manj kot 6 % pa se jih izloči z urinom.
English: Effects on prothrombin time may develop over several weeks if Optruma treatment is started in patients who are already on coumarin anticoagulant therapy.
Slovenian: Vplivi na protrombinski čas se lahko pokažejo šele čez nekaj tednov, če zdravljenje z zdravilom Optruma uvedemo pri bolnicah, ki so že na kumarinski antikoagulantni terapiji.
English: • Swelling of hands, feet and legs (peripheral oedema)
Slovenian: • Otekanje dlani, stopal in nog (periferni edem)
English: Optruma should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Slovenian: Zdravila Optruma ne bi smeli uporabljati pri bolnicah, ki kažejo znake ali imajo simptome raka endometrija, saj varnost zdravila pri tej skupini bolnic še ni bila zadosti raziskana.
English: Endometrial biopsies taken after six months therapy with Optruma 60 mg daily demonstrated nonproliferative endometrium in all patients.
Slovenian: Biopsija endometrija po šestih mesecih terapije z zdravilom Optruma v odmerku 60 mg na dan je pri vseh bolnicah pokazala neproliferativni endometrij.
English: Severe renal impairment.
Slovenian: Huda ledvična okvara.
English: Other medicines and Optruma
Slovenian: Druga zdravila in zdravilo Optruma
English: Elliptically shaped, white tablets imprinted with the code '4165'.
Slovenian: Eliptično oblikovane tablete bele barve, na katerih je odtisnjena šifra '4165'.
English: Increasing doses of raloxifene result in slightly less than proportional increase in the area under the plasma time concentration curve (AUC).
Slovenian: Povečevanje odmerkov raloksifena povzroči nekaj manj kot sorazmerno povečanje površine pod krivuljo plazemske koncentracije po času (AUC).
English: HDL cholesterol and triglyceride concentrations did not change significantly.
Slovenian: Koncentracije HDL holesterola in trigliceridov se niso značilno spremenile.
English: Teratology studies were conducted in rabbits and rats.
Slovenian: Raziskave teratogenih učinkov so opravili na kuncih in podganah.
English: Optruma was associated with reduced bone resorption and a mean positive shift in calcium balance of 60 mg per day, due primarily to decreased urinary calcium losses.
Slovenian: Uporaba zdravila Optruma je bila povezana z zmanjšano resorpcijo kostnega tkiva in s srednjim pozitivnim premikom ravnotežja kalcija za 60 mg na dan, kar je bilo predvsem posledica zmanjšane izgube kalcija z urinom.
English: Optruma is for use only by postmenopausal women and must not be taken by women who could still have a baby.
Slovenian: Zdravilo Optruma je namenjeno le ženskam po menopavzi in je ne smejo jemati ženske, ki bi še lahko zanosile.
English: In general, it does not change triglycerides or HDL ("good") cholesterol.
Slovenian: Na splošno ne vpliva na trigliceride ali HDL ('dobri') holesterol.
English: Nearly 3,000 transvaginal ultrasound (TVUs) examinations were evaluated from 831 women in all dose groups.
Slovenian: Proučili so rezultate skoraj 3.000 transvaginalnih ultrazvočnih preiskav pri 831 ženskah iz vseh skupin odmerjanja.
English: d) Effects on breast tissue
Slovenian: d) Vplivi na tkivo dojk
English: Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA): http://www.ema.europa.eu
English: Optruma could harm your unborn child.
Slovenian: Zdravilo Optruma lahko poškoduje vašega nerojenega otroka.
English: This leaflet was last revised in month YYYY.
Slovenian: Navodilo je bilo nazadnje revidirano dne {mesec/LLLL}
English: • Skin around the vein is red and painful (superficial vein thrombophlebitis)
Slovenian: • Koža okrog ven je rdeča in boleča (tromboflebitis povrhnjih ven)
English: However, if you have taken oestrogen in the past and had extreme elevations in triglycerides, you should talk to your doctor before taking Optruma.
Slovenian: Če ste v preteklosti že jemali estrogene in ob tem imeli močno zvišane vrednosti trigliceridov, se pred jemanjem zdravila Optruma pogovorite s svojim zdravnikom.
English: No data are available on the concomitant use of Optruma and agents used in the treatment of early or advanced breast cancer.
Slovenian: Tako ni podatkov o sočasnem zdravljenju z zdravilom Optruma in drugimi zdravili, ki se uporabljajo za zdravljenje zgodnjega ali napredovalega raka dojke.
English: ii) Bone Mineral Density (BMD): The efficacy of Optruma once daily in postmenopausal women aged up to 60 years and with or without a uterus was established over a two-year treatment period.
Slovenian: ii) Mineralna kostna gostota (BMD): Učinkovitost zdravljenja z zdravilom Optruma enkrat dnevno so ugotavljali pri ženskah po menopavzi, starih do 60 let, z maternico ali brez nje, in sicer med 2-letnim zdravljenjem s tem zdravilom.
English: BOTTLE LABEL, BOTTLE CARTON:
Slovenian: OZNAKA NA STEKLENIČKI, ŠKATLA STEKLENIČKE:
English: These results may have been confounded by baseline differences in BMD and vertebral fractures.
Slovenian: Ti rezultati so morda bili presenetljivi glede na osnovne razlike v BMD in zlome vretenc.
English: If you have been told by your doctor that you have an intolerance to lactose, a type of sugar, contact your doctor before taking this medicinal product.
Slovenian: Če vam je zdravnik povedal, da ne prenašate laktoze, ki je vrsta sladkorja, se pred uporabo tega zdravila posvetujte s svojim zdravilom.
English: 3 years.
Slovenian: do 60 mesecev.
English: After 4 years, raloxifene did not increase the risk of endometrial or ovarian cancer.
Slovenian: Po 4 letih raloksifen ni povečal tveganja za nastanek raka endometrija ali raka jajčnikov.
English: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Slovenian: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
English: Optruma has no effect on the risk of ER negative breast cancers.
Slovenian: Zdravilo Optruma ne vpliva na tveganje za ER negativne vrste raka dojke.
English: Three trials included 1,764 postmenopausal women who were treated with Optruma and calcium or calcium supplemented placebo.
Slovenian: V treh kliničnih preskušanjih je sodelovalo 1.764 žensk po menopavzi, ki so bile zdravljene z zdravilom Optruma in dodatki kalcija ali s placebom in dodatki kalcija.
English: The increase correlated with total bilirubin concentrations.
Slovenian: Povečanje je bilo v korelaciji s koncentracijami celokupnega bilirubina.
English: • Blood clot in an artery (for example stroke, including an increased risk of dying from stroke)
Slovenian: • Krvni strdek v arteriji (na primer kap), vključno s povečanim tveganjem za smrt zaradi kapi
English: • Decrease in the number of the platelets in the blood
Slovenian: • Zmanjšanje števila krvnih ploščic v krvi
English: Absolute bioavailability of raloxifene is 2 %.
Slovenian: Njegova absolutna biološka uporabnost je 2 %.
English: Replacement therapies generally reverse the excessive resorption of bone.
Slovenian: Nadomestne terapije na splošno zavrejo prekomerno resorpcijo kostnega tkiva.
English: For oral use Read the package leaflet before use.
Slovenian: Pred uporabo preberite priloženo navodilo!
English: Not all pack sizes may be marketed in all countries.
Slovenian: V vseh državah na trgu morda ni vseh navedenih pakiranj.
English: In addition, in a study with 2.5 x the recommended daily dose of Optruma there was no evidence of endometrial proliferation and no increase in uterine volume.
Slovenian: Poleg tega v raziskavi z 2,5-kratnim priporočenim dnevnim odmerkom zdravila Optruma ni bilo nobenih znakov proliferacije endometrija in niso ugotovili povečanja prostornine maternice.
English: Elderly: No dose adjustment is necessary for the elderly.
Slovenian: Pri starejših ni potrebna prilagoditev odmerkov.
English: As safety information regarding co-administration of raloxifene with systemic oestrogens is limited, such use is not recommended.
Slovenian: Ker so informacije v zvezi z varnostjo ob sočasnem jemanju raloksifena s sistemskimi estrogeni omejene, takšne kombinacije zdravljenja ne priporočamo.
English: • Hot flushes (vasodilatation)
Slovenian: • Navali vročine (vazodilatacija)
English: • If you are immobilised for some time such as being wheel-chair bound, needing to be admitted to a hospital or having to stay in bed while recovering from an operation or an unexpected illness as these may increase your risk of blood clots (deep vein thrombosis, pulmonary embolism or retinal vein thrombosis).
Slovenian: • Če ste dalj časa nepokretni, denimo uporabljate invalidski voziček, ste bili sprejeti v bolnišnico ali ležite v postelji pri okrevanju po operaciji ali zaradi nepričakovane bolezni, saj lahko to pri vas poveča tveganje za nastanek krvnih strdkov (tromboza globokih ven, pljučna embolija ali tromboza retinalnih ven).
English: • If you are suffering from breast cancer, as there is insufficient experience of Optruma use in women with this disease.
Slovenian: • Če imate raka dojke, ker ni zadosti izkušenj z uporabo zdravila Optruma pri ženskah s to boleznijo.
English: Bone loss is particularly rapid for the first 10 years after menopause when the compensatory increase in bone formation is inadequate to keep up with resorptive losses.
Slovenian: Izguba kostne mase je še posebej hitra v prvih 10 letih po menopavzi, ko proces kompenzacijskega povečanja tvorbe kostnega tkiva ne zadostuje, da bi nadomestil izgubo kostnega tkiva zaradi resorpcije.
English: What Optruma is and what it is used for What you need to know before you take Optruma How to take Optruma
Slovenian: Kaj je zdravilo Optruma in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Optruma Kako jemati zdravilo Optruma Možni neželeni učinki
English: This finding should be considered when prescribing raloxifene for postmenopausal women with a history of stroke or other significant stroke risk factors, such as transient ischemic attack or atrial fibrillation.
Slovenian: To ugotovitev je potrebno upoštevati pri predpisovanju raloksifena postmenopavzalnim ženskam z anamnezo kapi ali drugih značilnih dejavnikov tveganja za kap, kot so na primer tranzitorna ishemična ataka ali atrijska fibrilacija.
English: The tablets are for oral use.
Slovenian: Tablete so namenjene peroralni uporabi.
English: Concomitant use of vaginal oestrogen preparations was allowed in the clinical trial programme, if necessary to treat atrophic vaginal symptoms.
Slovenian: V programu kliničnih raziskav je bila sočasna uporaba vaginalnih pripravkov estrogena dovoljena, če je bilo to potrebno zaradi zdravljenja simptomov vaginalne atrofije.
English: In a population pharmacokinetic study, a 47 % decrease in lean body mass adjusted creatinine clearance resulted in a 17 % decrease in raloxifene clearance and a 15 % decrease in the clearance of raloxifene conjugates.
Slovenian: V populacijski farmakokinetični raziskavi je 47 % znižanje očistka kreatinina, prilagojenega telesni masi brez maščevja, povzročilo 17 % znižanje očistka raloksifena in 15 % znižanje očistka konjugatov raloksifena.
English: The female rodents in these studies were treated during their reproductive lives, when their ovaries were functional and highly responsive to hormonal stimulation.
Slovenian: Glodavske samice, ki so bile vključene v te raziskave, so zdravilo prejemale v rodni dobi, ko so njihovi ovariji še delovali in so se močno odzivali na stimulacijo s hormoni.
English: Optruma is not effective in reducing vasodilatation (hot flushes), or other symptoms of the menopause associated with oestrogen deficiency.
Slovenian: Optruma ni učinkovito zdravilo za zmanjševanje vazodilatacije (navalov vročine) ali drugih simptomov menopavze, ki so povezani s pomanjkanjem estrogena.
English: The two most frequent diagnoses associated with uterine bleeding during raloxifene treatment were endometrial atrophy and benign endometrial polyps.
Slovenian: Dve najpogostejši diagnozi, povezani s krvavitvijo iz maternice med zdravljenjem z raloksifenom, sta bili atrofija endometrija in benigni polipi endometrija.
English: Optruma belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor Modulators (SERMs).
Slovenian: Zdravilo Optruma sodi v skupino nehormonskih zdravil, imenovano selektivni modulatorji estrogenskega receptorja.
English: If you stop taking Optruma
Slovenian: Če ste prenehali jemati zdravilo Optruma
English: Tell your doctor if you are taking cholestyramine which is mainly used as lipid-lowering medicine, because Optruma may not work as well.
Slovenian: Obvestite svojega zdravnika, če jemljete holestiramin, ki se uporablja predvsem kot zdravilo za zniževanje koncentracij lipidov v krvi, saj zdravilo Optruma v tem primeru morda ne bo delovalo dovolj dobro.
English: Data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/or genespecific.
Slovenian: Podatki kažejo, da lahko estrogenski receptor regulira gensko ekspresijo po vsaj dveh različnih poteh, ki sta specifični za ligand, tkivo in/ali gen. a) Vplivi na okostje
English: Limited clinical data suggest that in patients with a history of oral oestrogen-induced hypertriglyceridemia (>5.6 mmol/l), raloxifene may be associated with a marked increase in serum triglycerides.
Slovenian: Omejeno število kliničnih podatkov kaže, da je pri bolnicah, ki so že imele s peroralnimi estrogeni povzročeno hipertrigliceridemijo (> 5,6 mmol/l), raloksifen lahko povezan z znatno povečanimi serumskimi trigliceridi.
English: There is no relevant use of Optruma in the paediatric population.
Slovenian: Uporaba zdravila Optruma ni primerna pri pediatrični populaciji.
English: c. Description of selected adverse reactions
Slovenian: c) Opis izbranih neželenih učinkov
English: Optruma should not be used in children of any age.
Slovenian: Zdravila Optruma ne smemo uporabljati pri otrocih katerekoli starosti.
English: Optruma (n = 317) was compared with continuous combined (n = 110) hormone replacement therapy (HRT) or cyclic (n = 205) HRT patients in some clinical trials.
Slovenian: Zdravilo Optruma (n = 317) so v nekaterih kliničnih preskušanjih primerjali s kontinuirano kombinirano (n = 110) hormonsko nadomestno terapijo (HRT - hormone replacement therapy) ali s ciklično HRT (n = 205).
English: It is unknown whether raloxifene/raloxifene metabolites are excreted in human milk.
Slovenian: Ni znano, ali se raloksifen/presnovki raloksifena izločajo v materino mleko.
English: Optruma reduced the incidence of clinical vertebral fractures by 35% compared with placebo (HR 0.65, CI 0.47
Slovenian: Zdravilo Optruma je zmanjšalo incidenco kliničnih zlomov vretenc za 35 % v primerjavi s placebom (HR 0,65, CI 0,47
English: As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen.
Slovenian: Kot selektivni modulator estrogenskega receptorja (SERM) deluje raloksifen bodisi kot selektivni agonist bodisi kot antagonist na tkiva, ki se odzivajo na estrogen.
English: (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000),
Slovenian: Za klasifikacijo neželenih učinkov smo uporabili naslednji dogovor: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko
English: Forty five women with osteoporosis or 15 women with osteoporosis with an existing fracture would need to be treated with Optruma for 3 years to prevent one or more vertebral fractures.
Slovenian: Da bi preprečili enega ali več zlomov vretenc, bi bilo treba z zdravilom Optruma zdraviti petinštirideset žensk z osteoporozo ali 15 žensk z osteoporozo in obstoječim zlomom 3 leta.
English: The table below gives the adverse reactions and frequencies observed in treatment and prevention studies involving over 13,000 postmenopausal women along with adverse reactions arising from postmarketing reports.
Slovenian: Spodnja tabela prikazuje neželene učinke in pogostnosti, ki so jih opazili v študijah zdravljenja in preprečevanja, v katerih je sodelovalo več kot 13.000 postmenopavzalnih žensk, vključno z neželenimi učinki iz poročil v obdobju trženja.Zdravljenje v teh študijah je trajalo od 6
English: Do not take Optruma if you are breast-feeding as it might be excreted in mother's milk.
Slovenian: Ne jemljite zdravila Optruma, če dojite, saj lahko zdravilo prehaja v materino mleko.
English: Compared to placebo there was no increased use in Optruma treated patients.
Slovenian: V primerjavi s placebom ni bila opažena povečana uporaba pri bolnicah, zdravljenih z zdravilom Optruma.
English: Optruma does not stimulate breast tissue.
Slovenian: Zdravilo Optruma ne stimulira tkiva dojk.
English: In contrast to the highly responsive ovaries in this rodent model, the human ovary after menopause is relatively unresponsive to reproductive hormonal stimulation.
Slovenian: V nasprotju z močno odzivnimi ovariji v tem glodavskem modelu pa je človeški (t. j. ženski) ovarij po menopavzi sorazmerno neodziven na stimulacijo s spolnimi hormoni.
English: Contents of the pack and other information What Optruma contains
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Optruma
English: Cholecystectomy rates for raloxifene (2.3 %) were not statistically significantly different from placebo (2.0 %).
Slovenian: (2,3 %) niso bile statistično značilno drugačne od placeba (2,0 %).
English: When a woman reaches the menopause, the level of the female sex hormone oestrogen goes down.
Slovenian: Ko pri ženski nastopi menopavza, upade koncentracija ženskega spolnega hormona estrogena.
English: The clinically most important adverse reactions reported in postmenopausal women treated with Optruma were venous thromboembolic events (see section 4.4), which occurred in less than 1% of treated patients.
Slovenian: Klinično najpomembnejši neželeni učinki, o katerih so poročali pri postmenopavzalnih ženskah, ki so se zdravile z zdravilom Optruma, so bili venski tromboembolični dogodki (glejte poglavje 4.4), ki so se pojavili pri manj kot 1 % zdravljenih bolnicah.
English: Raloxifene is a potent antioestrogen in the rat uterus and prevented growth of oestrogen-dependent mammary tumours in rats and mice.
Slovenian: Raloksifen deluje na podganji uterus kot močan antiestrogen in je preprečil rast od estrogena odvisnih tumorjev dojke pri podganah in miših.
English: • If you are allergic (hypersensitive) to raloxifene or any of the other ingredients of this medicine
Slovenian: • Če ste alergični (preobčutljivi) na raloksifen ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: • If you have any unexplained vaginal bleeding.
Slovenian: • Če imate kakršnokoli nerazložljivo krvavitev iz nožnice.
English: Raloxifene may cause foetal harm when administered to a pregnant woman.
Slovenian: Raloksifen lahko povzroči poškodbe ploda, če ga damo noseči ženski.
English: If you forget to take Optruma
Slovenian: Če ste pozabili vzeti zdravilo Optruma
English: Very common: Increased blood pressure a a Term(s) included based on postmarketing experience.
Slovenian: Zelo pogosti: zvišan krvni tlaka a Neželeni učinki so vključeni na podlagi izkušenj v obdobju trženja.
English: Optruma should be discontinued in the event of an illness or a condition leading to a prolonged period of immobilisation.
Slovenian: Zdravilo Optruma je treba prenehati jemati pri katerikoli bolezni ali motnji, ki vodi do daljše imobilizacije bolnice.
English: • If you have liver disease
Slovenian: • Če imate bolezen jeter.
English: It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues.
Slovenian: Kot agonist deluje na kosti in delno na presnovo holesterola (znižanje vrednosti skupnega holesterola in LDL holesterola), a ne v hipotalamusu ali v tkivih maternice ali dojke.
English: Although it may have no symptoms at first, osteoporosis makes you more likely to break bones, especially in your spine, hips and wrists and may cause back pain, loss of height and a curved back.
Slovenian: Četudi morda sprva ni nobenih simptomov, se zaradi osteoporoze poveča verjetnost zlomov kosti, še posebej v hrbtenici, kolku in zapestju, lahko pa povzroči tudi bolečine v hrbtu, zmanjšanje telesne višine in upognjenost hrbta.
English: Ink:
Slovenian: Črnilo:
English: Likewise, Optruma is indicated for the treatment of osteoporosis or established osteoporosis in women with BMD of the spine 2.5 SD below the mean value of a normal young population and/or with vertebral fractures, irrespective of BMD.
Slovenian: Podobno velja, da je zdravilo Optruma indicirano za zdravljenje osteoporoze ali ugotovljene osteoporoze pri ženskah, ki imajo vrednosti BMD za hrbtenico za 2,5 SD nižje od srednje vrednosti zdrave mlade populacije in/ali imajo zlome vretenc, ne glede na vrednosti BMD.
English: It does not matter what time of day you take your tablet but taking the tablet at the same time each day will help you remember to take it. You may take it with or without food.
Slovenian: Običajen odmerek zdravila je ena tableta na dan. Ni pomembno, ob katerem času jo vzamete, vendar vam bo jemanje vsak dan ob istem času pomagalo, da se spomnite, da morate vzeti zdravilo.
English: Like all medicines, this medicine can cause side effects although not everybody gets them.
Slovenian: Možni neželeni učinki Kot vsa zdravila ima lahko tudi zdravilo Optruma neželene učinke, ki pa se ne pojavijo pri vseh bolnicah.
English: Therapy should not be restarted until the initiating condition has resolved and the patient is fully mobile.
Slovenian: Terapije ne smemo ponovno uvesti, dokler bolnica popolnoma ne okreva od bolezni in je spet v celoti pokretna.
English: Concurrent administration of either calcium carbonate or aluminium and magnesium-hydroxide containing antacids do not affect the systemic exposure of raloxifene.
Slovenian: Sočasna uporaba antacidov, ki vsebujejo bodisi kalcijev karbonat bodisi aluminij in magnezijev hidroksid, ne vpliva na sistemsko razpoložljivost raloksifena.
English: Hepatic impairment including cholestasis.
Slovenian: Jetrna okvara, vključno s holestazo.
English: • Increased risk of blood clots in the lungs (pulmonary embolism)
Slovenian: • Povečano tveganje krvnih strdkov v pljučih (pljučna embolija)
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*.
Slovenian: Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.* 4.9 Preveliko odmerjanje
English: Ink: Shellac, propylene glycol, indigo carmine (E 132).
Slovenian: Črnilo: šelak, propilenglikol, indigotin (E132).
English: Raloxifene levels are maintained by enterohepatic recycling, giving a plasma half-life of 27.7 hours.
Slovenian: Koncentracija raloksifena se vzdržuje z enterohepatično cirkulacijo, zato je njegov plazemski razpolovni čas 27,7 ure.
English: • If you have active uterine cancer, as there is insufficient experience of Optruma use in women with this disease.
Slovenian: • Če imate aktivni rak maternice, saj pri ženskah s to boleznijo ni zadostnih izkušenj z uporabo zdravila Optruma.
English: The incidence of breast symptoms and uterine bleeding in raloxifene treated women was significantly lower than in women treated with either form of HRT.
Slovenian: Incidenca simptomov, povezanih z dojkami in krvavitvijo iz maternice, pri bolnicah, zdravljenih z raloksifenom, je bila značilno manjša kot pri ženskah, ki so bile zdravljene s katero od obeh oblik HRT.